Canopy Growth Corporation

Case Overview
49 Days Left to Seek Lead Plaintiff
Lead Plaintiff Deadline: | Lead Plaintiff Deadline: 06/03/2025 |
Status: | Status: Investigating |
Company Name: | Company Name: Canopy Growth Corporation |
Court: | Court: Eastern District of New York |
Case Number: | Case Number: 1:25cv01877 |
Class Period: | Class Period: 05/30/2024 - 02/06/2025 |
Ticker: | Ticker: CGC |
Related Attorneys: | Lead Attorneys: Thomas W. Elrod |
Related Practices: | Related Practices: Securities |
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Eastern District of New York on behalf of those who acquired Canopy Growth Corporation (“Canopy” or the “Company”) (NASDAQ:CGC) securities during the period from May 30, 2024, through February 6, 2025 (“the Class Period”). Investors have until June 3, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit.
In November 2024, Canopy announced that it had launched “award-winning California grown Claybourne brand” pre-rolled joints in Canada through an exclusive licensing agreement with Claybourne Co. (“Claybourne”).
On February 7, 2025, during pre-market hours, Canopy issued a press release announcing its financial results for the third quarter of its FY 2025. Among other items, Canopy reported that its “[g]ross margins decreased by 400 basis points to 32% in [Q3 2025] compared to [the same quarter the year prior] primarily due to the incremental costs related to the Claybourne infused pre-roll launch in Canada, and an increase in indirect costs of Storz & Bickel vaporizer devices[.]” These factors contributed to Canopy reporting a wider-than-anticipated Q3 2025 loss of C$1.11 per share compared to the C$0.48 per share loss estimated by analysts. During the same-day earnings call, Canopy’s Chief Financial Officer, Judy Hong, revealed that the Company’s Claybourne product launch costs were “primarily attributable to [the] higher initial cost to produce Claybourne” products. On this news, the price of Canopy shares declined by $0.76 per share, or approximately 27%, from $2.78 per share on February 6, 2025, to close at $2.02 on February 7, 2025.
The complaint alleges that defendants, throughout the Class Period, failed to disclose that: (1) Canopy had incurred significant costs producing Claybourne pre-rolled joints in connection with the Claybourne product launch in Canada; (2) the foregoing costs, in addition to certain indirect costs that Canopy incurred in connection with its Storz & Bickel vaporizer devices, were likely to have a significant negative impact on the Company’s gross margins and overall financial results ; and (iii) accordingly, Defendants had overstated the efficacy of Canopy's cost reduction measures and the health of its gross margins while downplaying issues with the same.
In November 2024, Canopy announced that it had launched “award-winning California grown Claybourne brand” pre-rolled joints in Canada through an exclusive licensing agreement with Claybourne Co. (“Claybourne”).
On February 7, 2025, during pre-market hours, Canopy issued a press release announcing its financial results for the third quarter of its FY 2025. Among other items, Canopy reported that its “[g]ross margins decreased by 400 basis points to 32% in [Q3 2025] compared to [the same quarter the year prior] primarily due to the incremental costs related to the Claybourne infused pre-roll launch in Canada, and an increase in indirect costs of Storz & Bickel vaporizer devices[.]” These factors contributed to Canopy reporting a wider-than-anticipated Q3 2025 loss of C$1.11 per share compared to the C$0.48 per share loss estimated by analysts. During the same-day earnings call, Canopy’s Chief Financial Officer, Judy Hong, revealed that the Company’s Claybourne product launch costs were “primarily attributable to [the] higher initial cost to produce Claybourne” products. On this news, the price of Canopy shares declined by $0.76 per share, or approximately 27%, from $2.78 per share on February 6, 2025, to close at $2.02 on February 7, 2025.
The complaint alleges that defendants, throughout the Class Period, failed to disclose that: (1) Canopy had incurred significant costs producing Claybourne pre-rolled joints in connection with the Claybourne product launch in Canada; (2) the foregoing costs, in addition to certain indirect costs that Canopy incurred in connection with its Storz & Bickel vaporizer devices, were likely to have a significant negative impact on the Company’s gross margins and overall financial results ; and (iii) accordingly, Defendants had overstated the efficacy of Canopy's cost reduction measures and the health of its gross margins while downplaying issues with the same.